When does tirzepatide patent expire in usa?

Short answer: there isn’t a single “tirzepatide patent expiry” date in the US. There are multiple patent families (composition of matter, methods of use, formulations, dosing, etc.), so expiries occur at different times. The key points:

- Core patent (composition of matter) for tirzepatide in the US is generally expected to run into the early-to-mid 2030s after patent term adjustments.
- Depending on term extensions (patent term adjustments and any pediatric exclusivity adjustments), the main patent could extend roughly into 2032–2036 or thereabouts.
- Other related patents (uses, dosing regimens, specific formulations) may expire earlier or later, but they do not all align to a single date.
- Even after patent expiry, regulatory exclusivity for biologics can delay generic/biosimilar entry. In the US, tirzepatide is a biologic, so 12-year data exclusivity can apply, which can push market entry of alternatives further into the 2030s, independent of patent expiry.

If you want a precise answer, I can pull the current US patent family details (with patent numbers and exact expiration dates) from Google Patents and the USPTO Patent Center. Just say “yes, look it up,” and I’ll fetch the specific expirations for the main tirzepatide patents and related families.